Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Oral Step-down Antibiotic Therapy Versus Continuing Intravenous Therapy for Uncomplicated Gram-negative Bacteraemia
NCT05199324Phase 4Completed
- Sponsor
- Tan Tock Seng Hospital
- Start
- Jun 2022
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 4, randomised, open-label trial of ciprofloxacin and trimethoprim + sulfamethoxazole in Gram-negative bacteremia (2 arms), sponsored by Tan Tock Seng Hospital. Primary endpoint: All-cause mortality at 30 days. Started Jun 2022; status: completed.
02
Drugs
ciprofloxacintrimethoprim + sulfamethoxazole
03
Conditions
Gram-negative bacteremia
Beyond the preview
Go deeper on NCT05199324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05199324.